EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer

Sijia Wu iD, Junnan Xu, Yiwen Ma, Guilian Liang, Jiaxing Wang, Tao Sun

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241282499 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 30.09.2024. Verfasst von Sijia Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Medicine Section One, Liaoning Cancer Hospital, Shenyang, Liaoning, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Medical Award Foundation, Shenyang Public Health R&D Special Project, Shenyang Breast Cancer Clinical Medical Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among women, breast cancer is the most prevalent form of a malignant tumour. Among the subtypes of breast cancer, hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative kinds make up the biggest proportion. The advent of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, which are dependent on cell cycle proteins, has greatly enhanced the prognosis of patients with advanced HR+/HER2− breast cancer. This is a specific treatment that stops the growth of cancer cells by preventing them from dividing. Nevertheless, the drug resistance of the disease unavoidably impacts the effectiveness of treatment and the prognosis of patients. This report provides a thorough analysis of the current research advancements about the resistance mechanism of CDK4/6 inhibitors in HR+/HER2− breast cancer. It presents an in-depth discussion from numerous viewpoints, such as aberrant cell cycle regulation and changes in signalling pathways. In response to the drug resistance problem, subsequent treatment strategies are also being explored, including switching to other CDK4/6 inhibitor drugs, a combination of novel endocrine therapeutic agents, an optimal combination of targeted therapies and switching to chemotherapy. An in-depth study of the resistance mechanism can assist in identifying creative tactics that can overcome or postpone drug resistance, alleviate the problem of restricted treatment strategies following drug resistance and enhance the prognosis of patients.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorsbreast cancerdrug resistanceendocrine therapyhormone receptor-positivetargeted therapy

Autor:innen und Institutionen

  • Breast Medicine Section One, Liaoning Cancer Hospital, Shenyang, Liaoning, China.
  • Breast Medicine Section One, Liaoning Cancer Hospital, Shenyang, Liaoning 110000, China.

ORCID-Profile: Sijia Wu

Förderung

  • Beijing Medical Award Foundation
  • Shenyang Public Health R&D Special Project
  • Shenyang Breast Cancer Clinical Medical Research Center
  • Fundamental Researsh Funds for the Central Universities
  • Liaoning Revitalization Talents Program
  • Liaoning Province Key Laboratory Project of Breast Cancer Research

Zitieren

APA

Wu, S., Xu, J., Ma, Y., Liang, G., Wang, J., & Sun, T. (2024). Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241282499

Vancouver

Wu S, Xu J, Ma Y, Liang G, Wang J, Sun T. Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241282499

BibTeX
@article{Wu2024,
  author = {Wu, Sijia and Xu, Junnan and Ma, Yiwen and Liang, Guilian and Wang, Jiaxing and Sun, Tao},
  title = {Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241282499}
}
Kostenlos starten →